Logo
Unionpedia
Communication
Get it on Google Play
New! Download Unionpedia on your Androidâ„¢ device!
Free
Faster access than browser!
 

Renal cell carcinoma and Varlilumab

Shortcuts: Differences, Similarities, Jaccard Similarity Coefficient, References.

Difference between Renal cell carcinoma and Varlilumab

Renal cell carcinoma vs. Varlilumab

Renal cell carcinoma (RCC) is a kidney cancer that originates in the lining of the proximal convoluted tubule, a part of the very small tubes in the kidney that transport primary urine. Varlilumab (CDX-1127) (INN) is a monoclonal antibody designed for immunotherapy for solid tumors and hematologic malignancies.

Similarities between Renal cell carcinoma and Varlilumab

Renal cell carcinoma and Varlilumab have 3 things in common (in Unionpedia): Immunotherapy, Nivolumab, World Health Organization.

Immunotherapy

Immunotherapy is the "treatment of disease by inducing, enhancing, or suppressing an immune response".

Immunotherapy and Renal cell carcinoma · Immunotherapy and Varlilumab · See more »

Nivolumab

Nivolumab, marketed as Opdivo, is a medication used to treat cancer.

Nivolumab and Renal cell carcinoma · Nivolumab and Varlilumab · See more »

World Health Organization

The World Health Organization (WHO; French: Organisation mondiale de la santé) is a specialized agency of the United Nations that is concerned with international public health.

Renal cell carcinoma and World Health Organization · Varlilumab and World Health Organization · See more »

The list above answers the following questions

Renal cell carcinoma and Varlilumab Comparison

Renal cell carcinoma has 199 relations, while Varlilumab has 9. As they have in common 3, the Jaccard index is 1.44% = 3 / (199 + 9).

References

This article shows the relationship between Renal cell carcinoma and Varlilumab. To access each article from which the information was extracted, please visit:

Hey! We are on Facebook now! »